Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.53 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.46 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26658400 | 1.00 | CRBN (0.57) | CRBNESR1IKZF2IKZF1GSPT1 | |
| SCHEMBL26658501 | 1.00 | CRBN (0.57) | CRBNESR1IKZF2IKZF1GSPT1 | |
| SCHEMBL26658402 | 1.00 | CRBN (0.57) | CRBNESR1IKZF2IKZF1GSPT1 | |
| SCHEMBL27466316 | 0.92 | CRBN (0.55) | CRBNESR1IKZF2 | |
| SCHEMBL24046445 | 0.91 | CRBN (0.63) | CRBNESR1 | |
| SCHEMBL30747130 | 0.91 | CRBN (0.63) | CRBNESR1 | |
| SCHEMBL30646886 | 0.91 | CRBN (0.63) | CRBNESR1 | |
| SCHEMBL29614668 | 0.91 | CRBN (0.63) | CRBNESR1 | |
| SCHEMBL26658534 | 0.91 | CRBN (0.63) | CRBNESR1 | |
| SCHEMBL26649398 | 0.91 | CRBN (0.63) | CRBNESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522621-A1 | 6,6A,7,8,9,10-HEXAHYDRO-5H-PYRAZINO[1',2':4,5]PYRAZINO[2,3-C]PYRIDAZINE DERIVATIVES AS SMARCA4 PROTEIN DEGRADERS FOR THE TREATMENT OF CANCER | Prelude Therapeutics Incorporated (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220577-A1 | 6,6A,7,8,9,10-HEXAHYDRO-5H-PYRAZINO[1',2':4,5]PYRAZINO[2,3-C]PYRIDAZINE DERIVATIVES AS SMARCA4 PROTEIN DEGRADERS FOR THE TREATMENT OF CANCER | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-11-16 | — | — | WO | disclosed |